This study from MD Anderson reported treatment results of 99 patients with prostate cancer treated with PT and a low-dose-rate (LDR) brachytherapy boost. Thirty-five patients had intermediate-risk (4 favorable and 31 unfavorable), 56 high-risk, and 8 very high-risk disease. At a median follow-up time of 45 months, 5-year biochemical recurrence-free survival was 98%. There was no local recurrence, distant metastasis, or cancer death. Four patients had acute urinary retention after brachytherapy procedure. Eleven patients (11%) had late grade 2 GU toxicity, and 3 (3%) had late grade 2 GI toxicity. One patient had grade 3 urethral stricture requiring dilatation and transurethral resection. The authors concluded that PT with LDR boost produced high control rates and low toxicity for men with prostate cancer.